Edison Investment Research - CASI Pharmaceuticals (CASI) CASI Pharmaceuticals - Evomela shows a strong launch

Report

Edison Investment Research

Sean Conroy

CASI Pharmaceuticals - Evomela shows a strong launch

CASI announced earnings for Q319 that included the first revenue generated by Evomela (melphalan) since its launch in mid-August: $2.7m. This is a highly encouraging number given it only represents a few weeks of sales. The product is approved as a conditioning agent in patients with multiple myeloma prior to stem cell transplant, and it is currently the only form of melphalan commercially available in China. This marks the transition of CASI into a commercial stage company

16/12/2019 6 EN

Underlying

CASI Pharmaceuticals

CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.

See profile

US14757U1097 NASDAQ Stock Market United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

SmartInsider

CASI Pharmaceuticals Inc: 1 director

A director at CASI Pharmaceuticals Inc bought 55,573 shares at 4.133USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Free Trial

September 9, 2022 September 9, 2022 1 EN

Edison Investment Research

CASI Pharmaceuticals - Termination of coverage

Edison Investment Research is terminating coverage on Hepion Pharmaceuticals (HEPA), Hurricane Energy (HUR), CASI Pharmaceuticals (CASI) and Monarch Mining Corporation (GBAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

September 23, 2021 September 23, 2021 2 EN

Edison Investment Research

CASI Pharmaceuticals - Termination of coverage

September 23, 2021 September 23, 2021 2 EN

HgT - Steady earnings growth, stable market multiples

HgT reported sustained healthy earnings momentum across its major holdings (driven primarily by upselling and cross-selling opportunities), contributing 5pp to its NAV performance in Q324. Its top 20 holdings (which make up 76% of its portfolio value) posted last 12-month sales growth of 20% (of which 12% was organic) and 24% EBITDA growth to end-September 2024, achieved at a 34% average EBITDA margin. The positive earnings impact on NAV was offset by adverse currency movements (sterling strengthening) of 3pp, the main contributor to the 0.9% NAV total return (TR) decline in Q324. The negative...

November 7, 2024 November 7, 2024 1 EN

Toby Thorrington

Toby Thorrington

Singapore Post - Results boosted by M&A and reduced losses

Singapore Post’s H1 trading was ‘resilient’, despite challenging market conditions across several of its businesses. Revenue increased by 20%, mainly due to the inclusion of the March 2024 acquisition of Border Express. This fed through to operating profit growth, which was up more than 60%. Divisional profit performance was mixed due to a number of issues but benefit was generated from internal initiatives and the postal rate increase introduced last year. However, there was no new news of the ongoing review of the Australian business.

November 7, 2024 November 7, 2024 1 EN

Toby Thorrington

Toby Thorrington

Information Services Corporation - Continued momentum in earnings growth

Information Services Corporation (ISC) delivered another quarter of robust growth in Q324, with revenue advancing 12% y-o-y to C$60.9m and adjusted EBITDA rising 18% to C$22.7m. Net income remained relatively flat at C$4.2m (translating to C$0.23 basic and diluted EPS) as ISC’s strong operational performance was offset by increases in share-based compensation expenses, increased investment in project delivery within its Technology Solutions segment and elevated amortisation costs related to the Master Service Agreement (MSA) extension. Management reiterated its revenue (C$240–250m) and adjuste...

November 7, 2024 November 7, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CASI Pharmaceuticals - Evomela shows a strong launch

CASI Pharmaceuticals Inc: 1 director

CASI Pharmaceuticals - Termination of coverage

CASI Pharmaceuticals - Termination of coverage

HgT - Steady earnings growth, stable market multiples

Singapore Post - Results boosted by M&A and reduced losses

Information Services Corporation - Continued momentum in earnings growth

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe